Q-omics provides the consensus-scored CCDC74B profile across patient tissues and cancer cell-line models. CCDC74B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CCDC74B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC74B RNA expression shows 16,090 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BLCA, KICH, and KIRP as cancer lineages where CCDC74B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC74B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC74B survival associations across molecular data types. CCDC74B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC74B RNA expression–survival associations across cancer types. High CCDC74B expression shows unfavorable associations in BLCA, KICH, ACC and HNSC, but favorable associations in BRCA and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CCDC74B RNA expression.
This table summarizes CCDC74B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC74B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC74B shows lower tumor expression in KICH, LUAD and THCA and higher tumor expression in KIRC, BRCA and COAD. The KICH box plot shows higher CCDC74B RNA expression in normal versus tumor tissue (log2 FC = −1.758, t-test p < 0.001).
This table shows molecular features associated with CCDC74B in patient tissues and cancer cell lines. In patient samples, CCDC74B shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC74B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
